Phase 2 KRAS P.G12C Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 2
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Non-Small Cell Lung Cancer (Stage III)KRAS P.G12C
Fundación GECP19 enrolled20 locationsNCT05398094
Recruiting
Phase 2
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Pancreatic CancerSolid TumorKRAS P.G12C
Allist Pharmaceuticals, Inc.88 enrolled31 locationsNCT06008288
Recruiting
Phase 1Phase 2
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd442 enrolled52 locationsNCT05410145
Recruiting
Phase 2
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Non-small Cell Lung CancerKRAS P.G12C
Gustave Roussy, Cancer Campus, Grand Paris40 enrolled5 locationsNCT05631249
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Colorectal, CancerNon-small Cell Lung CancerKRAS P.G12C+1 more
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205